Advertisement
Canada markets open in 6 hours 23 minutes

  • S&P/TSX

    21,788.48
    -60.11 (-0.28%)
     

  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     

  • DOW

    39,112.16
    -299.05 (-0.76%)
     

  • CAD/USD

    0.7319
    -0.0004 (-0.06%)
     

  • CRUDE OIL

    81.37
    +0.54 (+0.67%)
     

  • Bitcoin CAD

    84,088.07
    +500.46 (+0.60%)
     

  • CMC Crypto 200

    1,277.28
    -6.50 (-0.51%)
     

  • GOLD FUTURES

    2,327.60
    -3.20 (-0.14%)
     

  • RUSSELL 2000

    2,022.35
    -8.47 (-0.42%)
     

  • 10-Yr Bond

    4.2380
    -0.0100 (-0.24%)
     

  • NASDAQ futures

    20,015.25
    +43.00 (+0.22%)
     

  • VOLATILITY

    12.84
    -0.49 (-3.68%)
     

  • FTSE

    8,247.79
    0.00 (0.00%)
     

  • NIKKEI 225

    39,667.07
    +493.92 (+1.26%)
     

  • CAD/EUR

    0.6842
    +0.0010 (+0.15%)
     

Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference

Belite Bio, Inc
·1 min read
Belite Bio, Inc
Belite Bio, Inc

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference being held virtually on May 21 and 22, 2024. The Company will host a fireside chat at 3:00 pm ET on May 21, 2024.

About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com